The Medical Letter on Drugs and Therapeutics
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
February 8, 2010 (Issue: 1331)Asenapine (Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.